Starboard Delivers Open Letter to Bristol-Myers Squibb Stockholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Bristol-Myers Squibb (BMY) Responded to Starboard's Letter, Confident in Combination with Celgene (CELG)
February 28, 2019 12:00 PM ESTBristol-Myers Squibb Company (NYSE: BMY) today issued the following statement in response to a letter from Starboard Value:
Bristol-Myers Squibb welcomes the opinions of all of its stockholders and will review Starboards letter and respond in due course.
The Bristol-Myers Squibb Board and management team are confident that our combination with Celgene Corporation (NASDAQ: CELG) will create a premier biopharma company and deliver substantial benefits to our stockholders. This combination is consistent with our strategy and is the... More
